Aberrant Expression of CD133 in Non-small Cell Lung Cancer and Its Relationship to Vasculogenic Mimicry

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2012 Nov 23

PMID 23170850

Citations 60

Authors

Shiwu Wu

Lan Yu

Danna Wang

Lei Zhou

Zenong Cheng

Damin Chai

Li Ma

Yisheng Tao

Affiliations

Soon will be listed here.

Abstract

Background: To investigate on expressions and clinical significances of CD133 protein and vasculogenic mimicry (VM) in primary non-small cell lung cancer (NSCLC).

Methods: The specimens of NSCLC from 305 Chinese patients with follow-up were analyzed for CD133 protein expression and VM by immunohistochemical and histochemical staining.

Results: In NSCLC, positive rates of 48.9% and 35.7% were obtained for CD133 and VM, respectively. The VM and expression of CD133 were significantly higher in carcinoma than in normal. There were a positive relationship between the VM and expression of CD133 and the tumor grade, lymph node metastasis and clinical stage (all P<0.05). The overall mean survival time of the patients with CD133 and VM positive expression was lower than that of patients with negative expression. Microvessel density (MVD) was positive corresponded with the grade, lymph node metastasis and clinical stage (all P<0.05). The overall mean survival time of the patients with MVD≥22's group was shorter than that of patients with MVD<22's group. Pathological-tumor-node-metastasis (pTNM) stage, positive expression of CD133 and VM, postoperative therapy and MVD were independent prognostic factors of NSCLC (P<0.05). Immunohistochemistry revealed an important intratumoral heterogeneity in all four CD133 expression profiles.

Conclusions: VM, MVD and expression of CD133 are related to differentiation, lymph node metastasis, clinical stage, and prognosis. It is suggested that CD133, VM and MVD should be considered as a potential marker for the prognosis.

Citing Articles

The role of N6-methyladenosine modification in tumor angiogenesis.

Qin L, Zeng X, Qiu X, Chen X, Liu S Front Oncol. 2024; 14:1467850.

PMID: 39691597 PMC: 11649548. DOI: 10.3389/fonc.2024.1467850.

Mechanisms of angiogenesis in tumour.

Zhang R, Yao Y, Gao H, Hu X Front Oncol. 2024; 14:1359069.

PMID: 38590656 PMC: 10999665. DOI: 10.3389/fonc.2024.1359069.

EGR1 Regulation of Vasculogenic Mimicry in the MDA-MB-231 Triple-Negative Breast Cancer Cell Line through the Upregulation of KLF4 Expression.

Jung E, Han Lee Y, Ou S, Kim T, Shin S Int J Mol Sci. 2023; 24(18).

PMID: 37762678 PMC: 10532327. DOI: 10.3390/ijms241814375.

Live-cell imaging-based dynamic vascular formation assay for antivascular drug evaluation and screening.

Li Z, Zhang H, Sun Y, Feng Z, Cui B, Han J iScience. 2023; 26(5):106721.

PMID: 37216092 PMC: 10193242. DOI: 10.1016/j.isci.2023.106721.

SNORD17-mediated KAT6B mRNA 2'-O-methylation regulates vasculogenic mimicry in glioblastoma cells.

Cui J, Liu X, Dong W, Liu Y, Ruan X, Zhang M Cell Biol Toxicol. 2023; 39(6):2841-2860.

PMID: 37058271 DOI: 10.1007/s10565-023-09805-w.

References

Wang X, Penalva L, Yuan H, Linnoila R, Lu J, Okano H . Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. Mol Cancer. 2010; 9:221. PMC: 2939568. DOI: 10.1186/1476-4598-9-221. View

Sagrinati C, Netti G, Mazzinghi B, Lazzeri E, Liotta F, Frosali F . Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol. 2006; 17(9):2443-56. DOI: 10.1681/ASN.2006010089. View

Fan Y, Sun W . Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy. World J Gastrointest Surg. 2010; 2(4):117-27. PMC: 2999229. DOI: 10.4240/wjgs.v2.i4.117. View

Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A . Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer. 2007; 18(3):506-14. DOI: 10.1111/j.1525-1438.2007.01056.x. View

Liu W, Xu G, Ma J, Jia W, Li J, Chen K . Osteopontin as a key mediator for vasculogenic mimicry in hepatocellular carcinoma. Tohoku J Exp Med. 2011; 224(1):29-39. DOI: 10.1620/tjem.224.29. View

Scadden D . Cancer stem cells refined. Nat Immunol. 2004; 5(7):701-3. DOI: 10.1038/ni0704-701. View

Wu N, Zhao X, Liu M, Liu H, Yao W, Zhang Y . Role of microRNA-26b in glioma development and its mediated regulation on EphA2. PLoS One. 2011; 6(1):e16264. PMC: 3021542. DOI: 10.1371/journal.pone.0016264. View

Ramalingam S, Owonikoko T, Khuri F . Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin. 2011; 61(2):91-112. DOI: 10.3322/caac.20102. View

Zhu P, Ning Y, Yao L, Chen M, Xu C . The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia. J Exp Clin Cancer Res. 2010; 29:124. PMC: 2944817. DOI: 10.1186/1756-9966-29-124. View

10.

Okita K, Ichisaka T, Yamanaka S . Generation of germline-competent induced pluripotent stem cells. Nature. 2007; 448(7151):313-7. DOI: 10.1038/nature05934. View

11.

Yue W, Chen Z . Does vasculogenic mimicry exist in astrocytoma?. J Histochem Cytochem. 2005; 53(8):997-1002. DOI: 10.1369/jhc.4A6521.2005. View

12.

Schneider M, Huber J, Hadaschik B, Siegers G, Fiebig H, Schuler J . Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker. BMC Cancer. 2012; 12:96. PMC: 3368744. DOI: 10.1186/1471-2407-12-96. View

13.

Sun W, Fan Y, Zhang W, Ge C . A pilot histomorphology and hemodynamic of vasculogenic mimicry in gallbladder carcinomas in vivo and in vitro. J Exp Clin Cancer Res. 2011; 30:46. PMC: 3098797. DOI: 10.1186/1756-9966-30-46. View

14.

Gray D, Huss W, Yau J, Durham L, Werdin E, Funkhouser Jr W . Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis. Cancer Res. 2004; 64(5):1712-21. DOI: 10.1158/0008-5472.can-03-2700. View

15.

Horst D, Kriegl L, Engel J, Kirchner T, Jung A . CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 2008; 99(8):1285-9. PMC: 2570510. DOI: 10.1038/sj.bjc.6604664. View

16.

Mineo T, Ambrogi V, Baldi A, Rabitti C, Bollero P, Vincenzi B . Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol. 2004; 57(6):591-7. PMC: 1770311. DOI: 10.1136/jcp.2003.013508. View

17.

Moriyama T, Ohuchida K, Mizumoto K, Cui L, Ikenaga N, Sato N . Enhanced cell migration and invasion of CD133+ pancreatic cancer cells cocultured with pancreatic stromal cells. Cancer. 2010; 116(14):3357-68. DOI: 10.1002/cncr.25121. View

18.

Park I, Zhao R, West J, Yabuuchi A, Huo H, Ince T . Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2007; 451(7175):141-6. DOI: 10.1038/nature06534. View

19.

Ito Y, Hamazaki T, Ohnuma K, Tamaki K, Asashima M, Okochi H . Isolation of murine hair-inducing cells using the cell surface marker prominin-1/CD133. J Invest Dermatol. 2006; 127(5):1052-60. DOI: 10.1038/sj.jid.5700665. View

20.

Ricci-Vitiani L, Lombardi D, Pilozzi E, Biffoni M, Todaro M, Peschle C . Identification and expansion of human colon-cancer-initiating cells. Nature. 2006; 445(7123):111-5. DOI: 10.1038/nature05384. View